| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
Benzenesulfonamide, 4-[5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- manufacturers
- Enflicoxib
-
- $160.00
-
2026-05-09
- CAS:251442-94-1
- Purity: 99.27%
- Supply Ability: 10g
|
| | Benzenesulfonamide, 4-[5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- Basic information |
| | Benzenesulfonamide, 4-[5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- Chemical Properties |
| Boiling point | 461.4±55.0 °C(Predicted) | | density | 1.57±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 100 mg/mL (246.71 mM; ultrasonic and warming and heat to 60°C) | | pka | 10.39±0.10(Predicted) | | form | Solid | | color | White to off-white | | SMILES | O=S(N)(C1=CC=C(N2N=C(C(F)(F)F)CC2C3=CC=C(C=C3F)F)C=C1)=O |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Acute Tox. 4 Oral
STOT RE 2 |
| | Benzenesulfonamide, 4-[5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- Usage And Synthesis |
| Uses | Enflicoxib (E 6087) is a nonsteroidal anti-inflammatory compound that selectively inhibits cyclooxygenase-2 (COX-2).Enflicoxib does not inhibit cyclooxygenase-1 (COX-1). E-6087 shows anti-inflammatory, analgesic and antipyretic activities in animal models[1]. | | Biological Activity | Orally available, potent and selective cyclooxygenase 2 (COX-2) inhibitor | | in vivo | E-6132, one of Enflicoxib (E-6087) metabolites, also inhibits COX-2.After single oral administration of 5 mg/kg of E-6087 to rats, plasma concentrations of Enflicoxib at peak time are higher than those of E-6132, suggesting that activity is mainly due to Enflicoxib[1].
Enflicoxib (E-6087) is characterized by a long elimination half-life (20-35 h), a low plasma clearance (0.10-0.22 L/h/kg) and a relatively large volume of distribution (2-6 L/kg) in rats and dogs after single oral and intravenous doses. Enflicoxib and E-6132 (a pharmacologically active metabolite) show different pharmacokinetics. The higher percentage of Enflicoxib at early times suggests that Enflicoxib is the main compound responsible for in vivo activity, although E-6132 would contribute to the activity at later times[2]. | Animal Model: | Male and female Wistar rats (250 g)[1] | | Dosage: | 5 mg/kg | | Administration: | Administered by gastric gavage (10 mL/kg); a single oral dose | | Result: | Plasma concentrations of E-6087 at peak time are higher than those of E-6132.
|
| | IC 50 | COX-2 | | References | [1] Carlos Pérez-Maseda,et al. Determination of enantiomeric purity of a novel COX-2 anti-inflammatory drug by capillary electrophoresis using single and dual cyclodextrin systems. Electrophoresis.2003 May;24(9):1416-21. DOI:10.1002/elps.200390182
[2] R F Reinoso,et al. Pharmacokinetics of E-6087, a new anti-inflammatory agent, in rats and dogs. Biopharm Drug Dispos.2001 Sep;22(6):231-42. DOI:10.1002/bdd.258 |
| | Benzenesulfonamide, 4-[5-(2,4-difluorophenyl)-4,5-dihydro-3-(trifluoromethyl)-1H-pyrazol-1-yl]- Preparation Products And Raw materials |
|